Multicenter, Randomized, Double-blind, Placebo-controlled Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Auto Inflammatory Conditions: NLRC4 Mutation and XIAP Deficiency
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Tadekinig alfa (Primary)
- Indications Autoimmune disorders
- Focus Therapeutic Use
- Sponsors AB2 Bio
- 15 Jun 2017 Status changed from active, no longer recruiting to recruiting.
- 13 Jun 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Apr 2017 New trial record